Comparative Pharmacology
Head-to-head clinical analysis: LUZU versus OXISTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUZU versus OXISTAT.
LUZU vs OXISTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Luliconazole inhibits fungal lanosterol 14α-demethylase, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Oxiconazole is an azole antifungal that inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Apply a thin layer of luliconazole 1% cream to the affected skin once daily for 2 weeks (tinea pedis), 1 week (tinea cruris, tinea corporis).
Apply topically once daily for 2 weeks (tinea pedis, tinea cruris, tinea corporis) or 4 weeks (tinea versicolor).
None Documented
None Documented
The terminal elimination half-life is approximately 140 hours (range 130-177 hours); this long half-life supports once-daily dosing and provides sustained drug concentrations in the skin following topical application.
Terminal elimination half-life is 20–30 hours, supporting once-daily topical application.
Luliconazole is primarily eliminated via hepatic metabolism; renal excretion accounts for less than 1% of the dose; fecal excretion accounts for approximately 78-82% of the administered dose as metabolites; biliary excretion is a minor route.
Primarily hepatic metabolism; <1% excreted unchanged in urine; biliary/fecal elimination accounts for ~75% of dose.
Category C
Category C
Topical Antifungal
Topical Antifungal